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We congratulate Dr. Touchette and colleagues
for their economic analysis of alvimopan.1 We
wanted to clarify the questions and concerns
they raised about our previous economic analy-
sis of alvimopan.2 They expressed concern about
inconsistencies in our patient numbers. Our
total number of patients represented pooled data
from all patients in the modified intent-to-treat
populations from four phase III North American
efficacy trials who underwent bowel resection
and received placebo or alvimopan 12 mg
(labeled indication and dose).3–6 This
population was described previously by Dr.
Wolff and colleagues7 and is also noted in the
sponsor’s United States Food and Drug Adminis-
tration (FDA) briefing document used for the
alvimopan advisory committee meeting (Table
12.3.1; studies 14CL302, 14CL308, 14CL313,
and 14CL314).8
We did not include data from patients who
received alvimopan 6 mg or from patients who
underwent total abdominal hysterectomy
(nonapproved dose and indication). However,
these patients were included in the first three
phase III trials; as such, it appears that the data
inputs used by Dr. Touchette and colleagues
included data from these patients in addition to
patients who underwent bowel resection. Fur-
thermore, they did not include the largest and
most recently published phase III efficacy study
that evaluated alvimopan 12 mg only in patients
who underwent bowel resection (labeled dose
and indication).6 This study was included in our
economic evaluation.2
In North America, hospital discharge is clo-
sely linked to gastrointestinal recovery. There-
fore, treatments that accelerate gastrointestinal
recovery may shorten hospital length of stay.
Review of the European phase III efficacy study
showed that hospital length of stay was not
linked to gastrointestinal recovery,9 likely due to
regional variation in practice patterns along with
other differences that may impact decisions on
hospital discharge. Therefore, we did not
include these data in our economic analysis nor
was it included in the FDA’s evaluation of the
drug for hospital discharge end points.
We used two sources to estimate total hospital
costs for the pooled data in our analysis (day-
specific hospital cost estimates for bowel
resection procedures from Premier’s Perspective
Comparative Database and costs published in the
2007 U.S. Census Bureau statistical abstract for
2004, converted to 2007 dollars).2 Despite using
different data inputs, different patient data, and a
different analytic approach, Dr. Touchette and
colleagues’ overall results were consistent with
the conclusions from our analysis. Furthermore,
these results are consistent with results of other
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large database or institutional analyses of alvimo-
pan.10–12 Overall, the results of these analyses
suggest that use of alvimopan as indicated may
be cost-beneficial provided that length of stay is
reduced.
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